Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with multiple myeloma.
For the time being, the use of isatuximab in combination with pomalidomide and dexamethasone is not recommended for the treatment of adults with relapsed and refractory multiple myeloma who have been treated with lenalidomide and a proteasome inhibitor and whose disease has progressed on their last treatment.
